A study found that drug survival for adalimumab is significantly higher than infliximab in pediatric patients with hidradenitis suppurativa (HS). Adalimumab’s drug survival was 90.6% at 12 months and 78.3% at 24 months, while infliximab’s survival was 54.5% at 12 months and 36.4% at 24 months. Factors like older age, longer disease duration, higher BMI, and surgery during treatment were associated with increased drug survival. Certain limitations of the study included a small sample size and lack of adjustment for baseline disease severity and medication dosing. Further analysis will be conducted. No financial disclosures were reported by the researchers.
Source link
Drug Survival Rates in Pediatric Patients With HS Compared
